Background We previously reported that S-1 plus cisplatin was feasible as adjuvant chemotherapy for stage III gastric cancer after D2 gastrectomy. Herein we evaluate the recurrence-free survival and overall survival rates as secondary endpoints based on updated follow-up data. Methods Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled. Treatment consisted of 3 cycles of S-1 (40 mg/m 2 PO) twice daily on days 1-21 and cisplatin (60 mg/m 2 IV) on day 8, and S-1 was given on days 1-28 every 6 weeks until 1 year after surgery.
Introduction
In 2007, the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) demonstrated the efficacy of S-1 for stage II-III Gastric Cancer (GC) patients who underwent curative resection with D2 gastrectomy [1, 2] . The addition of S-1 improved the overall survival (OS) rate, with a low incidence of adverse events and good compliance. According to this result, in Japan, the currently recommended adjuvant treatment after D2 gastrectomy is S-1 for 1 year. However, the 5-year OS rates in stage III patients receiving S-1 have been less satisfactory: 67.1 and 50.2 % for stage IIIA and IIIB, respectively. Therefore, identification of more effective treatments for stage III GC is urgently needed. So firstly we evaluated the feasibility of S-1 plus cisplatin, that is now considered to be one of the standard regimens for metastatic or recurrent GC [3] as adjuvant chemotherapy for Stage III GC after D2 gastrectomy.
As results, treatment completion rates after 3 cycles of S-1 plus cisplatin were 72 % (42/58; 95 % CI: 60-84 %; 57 % [12/21] before and 81 % [30/37] after the protocol amendment). Grade 3/4 toxicities included neutropenia (40 %), anorexia (28 %), and febrile neutropenia (4 %) before the protocol amendment, and neutropenia (37 %), anorexia (8 %), and febrile neutropenia (3 %) after the amendment implementation. Therefore, we concluded that the amended S-1 plus cisplatin regimen is feasible as adjuvant chemotherapy [4] .
In this report, we evaluate the recurrence-free survival (RFS) and OS as secondary endpoints based on updated follow-up data.
Methods
Patients eligible for this trial had either stage IIIA (T2,N2; T3,N1; T4,N0) or stage IIIB (T3,N2; T4,N1) [5] gastric adenocarcinoma and had undergone D2 gastrectomy with R0 surgical resection. Additional details were described as previously [4] . The protocol was approved by the institutional review board at each participating center. Treatment according to the original protocol was initiated 4-8 weeks after surgery with 3 cycles of S-1 plus cisplatin (SP) followed by S-1 for up to 1 year. In the SP step, each cycle consisted of 40 mg/m 2 S-1 taken orally twice-daily for 21 days plus a 2-hour infusion of 60 mg/m 2 cisplatin on day 8. Each cycle was administered at 5-week intervals. In the S-1 step, 40 mg/m 2 S-1 was taken for 28 days at 6-week intervals. During enrollment, some toxicity was reported during the first cycle of SP, particularly neutropenia and anorexia. To minimize patient's risk, we elected to amend the protocol. Treatment according to the amended protocol was initiated 4-6 weeks after surgery and consisted of the following: the first cycle of chemotherapy consisted of S-1 monotherapy, and cisplatin was added to cycles 2, 3, and 4. After that, S-1 was administered for up to 1 year. Tumor assessments with ultrasonography, computed tomography, and GI endoscopy and radiography were performed every 6 months for first 2 years after surgery, and annually thereafter (maximum follow-up 5 years). RFS was defined as the time from enrollment to the recurrence or death, whichever occurred first. OS was defined as the time from enrollment to death from any cause.
Results
From August 2007 to July 2009, 63 patients (25 patients in the original protocol, 38 patients in the amended protocol) were accrued from five Japanese institutions. Overall, 34 patients (54 %) had stage IIIA disease and 25 (40 %) had stage IIIB disease. The patient clinical characteristics have been reported previously [4] . After enrollment, 5 patients were deemed ineligible due to confirmed stage II disease (n = 2), stage Ib disease (n = 1), stage IV disease (n = 1), and cancer other than GC (n = 1).
OS and RFS were analyzed in 58 eligible patients. At the time of data cut-off on July 31, 2012, 11 patients had died, 5 patients were alive with recurrence, and the remaining 42 patients were alive without recurrence. The median follow-up period was 46 months. All patients could be followed-up for at least 3 years from the date of surgery. Kaplan-Meier estimates are shown that the 3-year OS rate was 84.5 % (95 % CI: 72.3-91.6 %) (Fig. 1a) , and the 3-year RFS rate was 74.1 % (95 % CI: 60.8-83.5 %) (Fig. 1b) . According to disease stage, the 3-year OS rate of patients with stage IIIA disease was 87.9 % (95 % CI: 70.9-95.3 %) (Fig. 2a) , and the 3-year RFS rate was 81.8 % (95 % CI: 63.9-91.4 %) (Fig. 2b) . The 3-year OS rate of patients with stage IIIB disease was 80.0 % (95 % CI: 58.4-91.1 %) (Fig. 2a) . The 3-year RFS rate was 64.0 % (95 % CI: 42.2-79.4 %) (Fig. 2b) .
In addition, there was no significant difference in survival between the original protocol and the amended protocol. The 3-year OS rate of patients with stage IIIA disease in the original protocol (n = 16) and the amended (n = 17) was 87.5 and 88.2 %, respectively, and the 3-year RFS rate was 75.0 and 82.4 %, respectively. The 3-year OS rate of patients with stage IIIB disease was 80.0 % in the original protocol (n = 5) and the amended protocol (n = 20), and the 3-year RFS rate was 60.0 and 65.0 %, respectively.
The most common sites of relapse were the peritoneum (n = 8), hematogenous sites (n = 6), and lymph nodes (n = 4). Two patients experienced relapses simultaneously in the liver and the lymph nodes. No local relapse was observed. After relapse, the median survival time was estimated to be 351 days. Subsequent therapies were taxanes (n = 7), SP (n = 4), S-1 (n = 3), and CPT-11 (n = 1), and 1 case underwent surgery (oophorectomy) followed by paclitaxcel.
Discussion
In this study, postoperative S-1 plus 3 cycles of cisplatin demonstrated promising efficacy with respect to 3-year RFS and OS for stage III GC.
Recently, the results of the CLASSIC trial indicated that adjuvant capecitabine and oxaliplatin improved 3-year disease-free survival (DFS) compared with surgery alone in GC patients [6] . The subgroup analysis suggested that combined capecitabine and oxaliplatin were beneficial not only for stage II patients but also for stage IIIA and stage IIIB patients (the hazard rates compared to surgery alone were 0.57 and 0.57, respectively). This result suggests that combination therapy with fluoropyrimidine and a platinum agent may be more beneficial than fluoropyrimidine alone in patients with stage III disease after D2 gastrectomy.
Although small-sample comparisons should be made with caution, there was no significant difference in survival between the original protocol and the amended protocol. It is suggested that delay of cisplatin administration in our amended protocol didn't sacrifice the efficacy in terms of survival. Consequently, we believe that completion of 3 cycles of cisplatin is important, even though we changed the first cycle to S-1 monotherapy and delayed additional cisplatin until cycles 2, 3, and 4. Moreover, our amended protocol was beneficial in the reduction of grade 3/4 anorexia and nausea, even though we did not use NK-1 receptor antagonists, because they were not approved in Japan at that time. Now we could manage the cisplatin-induced emesis easier by using NK-1 receptor antagonists with this regimen.
In conclusion, adjuvant therapy with S-1 plus 3 cycles of cisplatin may reduce recurrence and improve survival in patients with stage III GC who underwent D2 gastrectomy. This treatment should be considered for use as an experimental arm for comparison to S-1 in future postoperative adjuvant phase III trials.
